Talphera Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
28.0%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.20next fiscal year
Monitoring Framework
Key Performance Indicators
NEPHRO CRRT Study Patient Enrollment Monthly35.0
Cash and Investments Balance Quarterly21.1MTarget: Sufficient through PMA approval
Watch Items
- NEPHRO CRRT Study CompletionTrigger: Completion of 70-patient enrollment and top-line data releaseAction: Evaluate top-line efficacy and safety data to prepare the Premarket Approval (PMA) submission to the FDA.
- CorMedix Exclusive Right of First NegotiationTrigger: 60-day period following completion and announcement of Phase 3 study resultsAction: Engage in exclusive discussions regarding a potential acquisition of Talphera by CorMedix.
Research as of 19 Jun 2026